icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Aug 27-29
Digital ILC 2020
Back grey_arrow_rt.gif
Efficacy and Safety of 24 Weeks Treatment with Oral TLR8 Agonist Selgantolimod (GS-9688, SLGN) in Virally Suppressed Adult Patients with Chronic Hepatitis B: A Phase 2 Study
  EASL - The Digital International Liver Congress, 27-29 August 2020
Reported by Jules Levin
Edward Gane,1 P. Rod Dubar,2 Anna E. Brooks,2 Yang Zhao,3 Susanna K. Tan,3 Audrey H. Lau,3 Jenny C. Yang3, Anuj Gaggar,3 Mani Subramanian,3 Shyam Kottilil,4 Lydia Tang4
1Auckland City Hospital, Auckland, New Zealand; 2School of Biological Sciences, Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand; 3Gilead Sciences, Inc., Foster City, CA, USA; 4Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA